Table 4

Results of landmark analyses of post–Allo-SCT to determine associations between achieving MRD-negative status using highly sensitive testing methodology and subsequent PFS

StudyNo. patients (% MRD-negative at landmark)MethodSensitivity, quantitative?Time point (months)PFSP value
Moreno et al 200649 * 22 (59%) Three- or 4-color FLC 10−4, yes 3-6 16 vs 75 months <.001 
17 (29%) ASO IGHV RQ-PCR 10−5, yes 3-6 19 months vs NR .02 
Farina et al 200953  29, all in CR (48%) Nested ASO IGHV PCR from BM 10−6-10−7, no 6 93% vs 46% at 24 months .012 and .037 
12 100% vs 57% at 24 months 
Dreger et al 201061  39 (69%) Four-color FLC from BM. 10−4, 12 months 10−4, yes 12 HR for event-free survival 0.13 if MRD negative .013 
Logan et al 201337  31 (48%) Consensus IGHV PCR using HTS from PB† 10−6, quantitative from ≥10−5 12 93 vs 38% at 50 months <.001 
StudyNo. patients (% MRD-negative at landmark)MethodSensitivity, quantitative?Time point (months)PFSP value
Moreno et al 200649 * 22 (59%) Three- or 4-color FLC 10−4, yes 3-6 16 vs 75 months <.001 
17 (29%) ASO IGHV RQ-PCR 10−5, yes 3-6 19 months vs NR .02 
Farina et al 200953  29, all in CR (48%) Nested ASO IGHV PCR from BM 10−6-10−7, no 6 93% vs 46% at 24 months .012 and .037 
12 100% vs 57% at 24 months 
Dreger et al 201061  39 (69%) Four-color FLC from BM. 10−4, 12 months 10−4, yes 12 HR for event-free survival 0.13 if MRD negative .013 
Logan et al 201337  31 (48%) Consensus IGHV PCR using HTS from PB† 10−6, quantitative from ≥10−5 12 93 vs 38% at 50 months <.001 
*

Fifteen patients having Allo-SCT had insufficient data to determine effect of MRD on survival. Data presented on patients having autologous stem cell transplant.

†

Cellular fraction of peripheral blood tested.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal